BW20030519002142  20030519T171429Z UTC



( BW)(PALL-CORPORATION)(PLC) Baylor College of Medicine Selects
Pall to Aid Human Genome Project

    Business Editors
    UK REGULATORY NEWS

   HOUSTON & EAST HILLS, N.Y.--(BUSINESS WIRE)--May 19, 2003--

The Human Genome Sequencing Center at the Baylor College of
Medicine (BCM HGSC) signed an agreement with Pall Corporation (NYSE:
PLL) to develop a customized sample preparation tool to speed work on
the Human Genome Project.
   
The multi-year agreement is valued at several million dollars. The
BCM HGSC is one of the world's leading research centers designated to
work on Phase II of the Human Genome Project.
   
The BCM HGSC currently operates 78 sequencing machines, 24 hours a
day, seven days a week, processing more than 2.5 million reactions
every month. Pall will collaborate with the BCM HGSC to develop a
customized 192-well plate specific to the Center's exacting
requirements. This new plate will increase research efficiency and, as
importantly, provide reliable tracking of the large amounts of data
generated by their work. Innovative tools that remove bottlenecks from
the research process are key to the race to unlocking the human
genome. Pall is currently supplying the Center with its AcroPrep(R) 96
filter plate while completing development of the AcroPrep 192-well
plate.
   
"We are pleased to take part in this collaborative effort with the
BCM HGSC. As a premier site for producing DNA sequences for key
genomes, their work will have tremendous impact on mankind, changing
the way we understand disease and the various life processes involved
in human existence, providing great potential for agriscience and
other commercial fields," said Ken Harris, President of Pall
Biosciences.
   
The Human Genome Research Institute designated BCM HGSC as one of
six pilot programs for the final phase of the Human Genome Project.
This phase of work is an extension of the original deciphering of the
human genome, the blue print for human life, announced in June 2000.
The project, now in Phase II, involves producing a "finished"
blueprint that reexamines and fills in the remaining gaps, increasing
the overall accuracy of the original information to greater than 99.9
percent.
   
Pall currently markets the AcroPrep 96-well plate and recently
launched AcroPrep 384-well plate for sample processing. Both formats
are available with multiple membrane options and well volumes to meet
various application needs.

About Pall Corporation
   
Pall Corporation is the global leader in the rapidly growing field
of filtration, separations and purification. Pall's business is
organized around two broad markets: Life Sciences and Industrial. The
Company provides leading-edge products to meet the demanding needs of
customers in biotechnology, pharmaceuticals, transfusion medicine,
semiconductors, municipal drinking water and aerospace. Total revenues
are $1.3 billion. The company is headquartered in East Hills, New
York, and has operations in more than 30 countries. Further
information can be found on its Web site
http://www.pall.com/laboratory/

   Short Name: Pall Corporation
   Category Code: MSC
   Sequence Number: 00004971
   Time of Receipt (offset from UTC): 20030519T160239+0100

    --30--ZW/uk*

    CONTACT: Pall Corporation

    KEYWORD: UNITED KINGDOM INTERNATIONAL EUROPE
    INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL MEDICAL DEVICES 
PHARMACEUTICAL              
    SOURCE: Pall Corporation

Today's News On The Net - Business Wire's full file on the Internet
                          with Hyperlinks to your home page.
                          URL: http://www.businesswire.com